Topline: In the Phase III FRUSICA-2 study (n=234) in second-line advanced renal cell carcinoma, fruquintinib plus sintilimab achieved a median PFS of 22.2 months versus 6.9 months with axitinib or everolimus (HR 0.373; p<0.0001). ORR was 60.5% versus 24.3% (p<0.0001), with a median DoR of 23.7 versus 11.3 months. Grade ≥3 TEAEs occurred in 71.4% on the combination versus 58.8% on the control. OS is immature (~20% maturity). Benefits were consistent across IMDC risk groups; median follow-up was 16.6 months. The news: HUTCHMED reported positive Phase III outcomes from the randomized, open-label, active-controlled FRUSICA-2 registration trial comparing fruquintinib plus sintilimab to axitinib or everolimus in patients who progressed after first-line therapy. The data will be presented at ESMO 2025 and have already supported acceptance of a New Drug Application by China’s NMPA for the combination in locally advanced or metastatic RCC after prior treatment. Strategically, this is a bid to establish a domestic VEGFR TKI–PD-1 doublet as the second-line standard in China, where treatment pathways and comparator norms differ from the U.S. and EU. The efficacy signal is unusually strong for a post–first-line setting, but the control arm—axitinib/everolimus—will prompt debate outside China given the widespread use of cabozantinib, tivozanib, or lenvatinib-based options in global practice after IO/TKI exposure. The design choice likely reflects Chinese standards and the need for a pragmatic registrational route rather than an attempt to calibrate against the most active global controls. Independent review of PFS mitigates open-label bias, but OS confirmation remains a key gating item for regulatory durability and eventual uptake. For stakeholders, Chinese sites and sponsors gain a clearly positive dataset that could consolidate second-line sequencing around a homegrown doublet with familiar toxicity management. CROs and vendors should anticipate demand for safety infrastructure—hypertension, hand–foot syndrome, hepatic and endocrine monitoring—commensurate with the 71% rate of grade ≥3 events typical of TKI/IO combinations. If approved, the combination will increase operational complexity for centers now navigating multiple doublets across lines of therapy, raising scheduling, AE triage, and dose-modification workload. For ex-China sponsors and regulators, the result underscores the growing divergence between China-specific registration strategies and global evidence standards. Fruquintinib’s ex-China rights are with Takeda, while sintilimab lacks broad Western approvals, making any global expansion contingent on pairing fruquintinib with a PD-1/PD-L1 agent that has a U.S./EU label or on running new combination studies aligned to Western SOC comparators. Next, watch for the ESMO readout to unpack prior-therapy strata (IO-only, TKI-only, or prior IO/TKI), subgroup durability, and dose-intensity, which will inform real-world sequencing decisions. OS maturation will determine whether the magnitude of PFS and response translates into survival benefit, a likely focus for NMPA and for any health technology assessments within China. Outside China, clarity on Takeda’s intentions in RCC, potential alternative PD-1 partners, and whether a head-to-head against globally favored controls is planned will signal the viability of a broader strategy. The unanswered questions are comparator relevance, long-term tolerability over 20+ months of therapy, and how payers and hospitals will absorb the operational load of another TKI–IO doublet in later lines.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
